NORML’s Emerging Clinical Applications For Cannabis And Cannabinoids

NORML is pleased to present the latest expanded/updated edition of the publication Emerging Clinical Applications for Cannabis & Cannabinoids — a comprehensive review of the latest peer-reviewed science specific to the safety and therapeutic efficacy of whole-plant cannabis and/or its components.
Author:
Updated:
Original:
Image placeholder title

By Paul Armentano, NORML Deputy Director

The 2015 updated edition includes two additional disease profiles (Parkinson’s disease and PTS) and includes summaries of an additional 50+ relevant clinical and/or preclinical trials specific to cannabinoids’ therapeutic utility. Several existing sections, such as Chronic Pain, Diabetes, and Epilepsy, have been significantly expanded since the last edition (January 2013). Also updated is the Introduction to the Endocannabinoid System (authored by Dustin Sulak, DO) and Why I Recommend Medical Cannabis (authored by Estelle Goldstein, MD).

With summaries and citations of well over 250 recent peer-reviewed studies, this updated publication is one of the most thorough and up-to-date source-books available specific to documenting the established therapeutic qualities of cannabis. The updated publication is available online here.

Individual sections of this publication may be accessed at the links below:

Author’s Introduction
Foreword
Introduction to the Endocannabinoid System
Why I Recommend Medical Cannabis
Alzheimer’s Disease
Amyotrophic Lateral Sclerosis
Chronic Pain
Diabetes Mellitus
Dystonia
Epilepsy
Fibromyalgia
Gastrointestinal Disorders
Gliomas/Cancer
Hepatitis C
Human Immunodeficiency Virus
Huntington’s Disease
Hypertension
Incontinence
Methicillin-resistant Staphyloccus aureus (MRSA)
Multiple Sclerosis
Osteoporosis
Parkinson’s Disease
Post-Traumatic Stress
Pruritus
Rheumatoid Arthritis
Sleep Apnea
Tourette’s Syndrome

Source: NORML - make a donation

Related